Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

Authors :: Jeremy S. Abramson
Scott R. Solomon
Jon E. Arnason
Patrick B Johnston
Bertram Glass
Alessandro Crotta
Sandrine Montheard
Alessandro Previtali
Fei Fei Liu
Julia Braverman
Shien Guo
Ling Shi
Manali Kamdar
Source :: Transplantation and Cellular Therapy. 28:S188-S189
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Subjects :: Transplantation
Molecular Medicine
Immunology and Allergy
Cell Biology
Hematology

Full Text Access

Tools